Sonoma PharmaceuticalsSNOA
13F holders, Q4 2025 (December 31)16holders −4
2new positions
6sold out
$3.64avg. 13F price*
At the end of Q4 2025, 16 institutions reported holding Sonoma Pharmaceuticals Inc. (SNOA) in their 13F filings, down 4 from Q3 2025. 2 opened new positions and 6 sold out. The largest holders were DRW Securities, LLC ($222K), Vanguard Group Inc. ($69K) and Geode Capital Management, LLC ($58K).
- Company
- Sonoma Pharmaceuticals Inc.
- CUSIP
- 83558L303
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2025 → Q4 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $43K |
| Exits | 6 | $6K |
All 13F filers, Q3 2025 → Q4 2025: 55,935 shares bought and 6,382 shares sold, net +49,553 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 16 holders
| DRW Securities, LLC | 0.02% | Add +257.2% | 60,977 | $222K |
| Vanguard Group Inc. | 0.00% | Reduce -9.5% | 18,887 | $69K |
| Geode Capital Management, LLC | 0.00% | Reduce -9.7% | 15,908 | $58K |
| McKinley Carter Wealth Services, Inc. | 0.00% | New | 11,193 | $41K |
| Global Retirement Partners, LLC | 0.00% | Add +76.3% | 772 | $3K |
| Osaic Holdings, Inc. | 0.00% | New | 500 | $2K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -74.9% | 385 | $1K |
| JPMorgan Chase & Co. | 0.00% | Reduce -1.6% | 121 | $440 |
| BlackRock, Inc. | 0.00% | No change | 113 | $411 |
| US Bancorp \de | 0.00% | No change | 25 | $91 |
| Bank of America Corp. | 0.00% | Add +5.9% | 18 | $65 |
| UBS Group AG | 0.00% | Reduce -94.4% | 6 | $22 |
| Morgan Stanley | 0.00% | No change | 4 | $15 |
| Quaker Wealth Management, LLC | 0.00% | No change | 3 | $11 |
| Danske Bank A/S | 0.00% | No change | 1 | $4 |
| Cwm, LLC | 0.00% | No change | 1 | $0 |
"% of holder's portfolio" is SNOA's weight in each manager's 13F, not the share of Sonoma Pharmaceuticals Inc. the manager owns.